urea has been researched along with k 134 compound in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hidaka, H; Inoue, Y; Kihara, Y; Kimura, Y; Koga, Y; Nishi, T; Okada, M; Tachibana, K; Tochizawa, S; Toga, K | 1 |
| Hidaka, H; Inoue, Y; Kimura, Y; Sudo, T; Tachibana, K; Tochizawa, S; Toga, K | 1 |
| Doi, T; Hidaka, H; Ikenoya, M; Miura, T; Nishio, M; Sawanobori, K | 1 |
| Inoue, Y; Iwai, T; Jibiki, M; Kudo, T; Sugano, N | 1 |
| Handa, M; Ikeda, Y; Okamura, Y; Watanabe, N; Yoshida, H | 1 |
| Brass, EP; Connor, JT; Cooper, LT; Hiatt, WR; Lewis, RJ; Murphy, JR; Teerlink, JR | 1 |
| Brass, EP; Cooper, LT; Hiatt, WR; Morgan, RE | 1 |
| Asanuma, A; Hara, T; Itoh, S; Kondo, S; Nakagawa, T; Sasaki, Y; Tanabe, S; Yoshida, H | 1 |
| Inoue, K; Itoh, S; Kondo, S; Sasaki, Y; Suzuki, H; Tanabe, S; Yoshida, H | 1 |
| Asanuma, A; Ashikawa, Y; Hidaka, H; Inoue, Y; Itoh, S; Nakagawa, T; Tanabe, S; Yoshida, H | 1 |
| Bugaeva, LI; Kataev, VA; Kharlamov, IV; Kuzubova, EA; Lavrova, EB; Mal'tsev, MV; Petrov, VI | 1 |
| Ferdousi, F; Isoda, H; Itoh, S; Yoshida, H | 1 |
2 trial(s) available for urea and k 134 compound
| Article | Year |
|---|---|
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
Topics: Ankle Brachial Index; Decision Support Techniques; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Humans; Intermittent Claudication; Maximum Tolerated Dose; Peripheral Arterial Disease; Phosphodiesterase 3 Inhibitors; Prospective Studies; Quinolines; Recovery of Function; Research Design; Russia; Time Factors; Treatment Outcome; United States; Urea; Walking | 2011 |
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Cilostazol; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Arterial Disease; Phosphodiesterase Inhibitors; Predictive Value of Tests; Quinolines; Recovery of Function; Russia; Tetrazoles; Time Factors; Treatment Outcome; United States; Urea; Walking | 2012 |
10 other study(ies) available for urea and k 134 compound
| Article | Year |
|---|---|
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Quinolones; Rabbits; Tetrazoles; Thrombosis; Urea | 1998 |
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Blood Platelets; Cells, Cultured; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 3; Humans; Isoenzymes; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinolines; Quinolones; Recombinant Proteins; Semicarbazides; Urea | 2000 |
Investigation of binding proteins for anti-platelet agent K-134 by Drug-Western method.
Topics: Amino Acid Sequence; Binding Sites; Carrier Proteins; CD36 Antigens; Cofilin 2; Collagen Type I; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Protein Binding; Quinolines; Recombinant Proteins; Urea | 2007 |
Effects of cilostazol and k-134 on reconstructive surgery using prosthetic grafts in the abdominal aorta of beagle dogs.
Topics: Animals; Aorta, Abdominal; Blood Vessel Prosthesis Implantation; Cilostazol; Male; Mice; Plastic Surgery Procedures; Platelet Aggregation Inhibitors; Postoperative Complications; Quinolines; Sutures; Tetrazoles; Thrombosis; Tunica Intima; Urea | 2008 |
Shear-dependent suppression of platelet thrombus formation by phosphodiesterase 3 inhibition requires low levels of concomitant Gs-coupled receptor stimulation.
Topics: Aspirin; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; GTP-Binding Protein alpha Subunits, Gs; Hemostasis; Humans; Ligands; Platelet Aggregation; Quinolines; Ristocetin; Shear Strength; Tirofiban; Tyrosine; Urea; von Willebrand Factor | 2011 |
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Topics: Administration, Oral; Animals; Blood Flow Velocity; Disease Models, Animal; Dose-Response Relationship, Drug; Hindlimb; Lauric Acids; Male; Muscle, Skeletal; Necrosis; Peripheral Arterial Disease; Phosphodiesterase 3 Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Quinolines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Time Factors; Urea; Vascular System Injuries; Vasodilation; Vasodilator Agents | 2012 |
K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
Topics: Animals; Disease Models, Animal; Hindlimb; Lameness, Animal; Male; Peripheral Arterial Disease; Phosphodiesterase 3 Inhibitors; Quinolines; Rats; Rats, Sprague-Dawley; Urea | 2012 |
K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.
Topics: Animals; Brain; Cerebral Infarction; Male; Mice; Mice, Inbred ICR; Phosphodiesterase 3 Inhibitors; Quinolines; Rats; Rats, Sprague-Dawley; Thrombosis; Urea | 2012 |
Effects of a New Benzimidazole Derivative with Actoprotective Properties on Spermatogenic Epithelium of the Testes and Fertility of Male White Rats.
Topics: Animals; Animals, Outbred Strains; Benzimidazoles; Cytoprotection; Dose-Response Relationship, Drug; Fertility; Male; Quinolines; Rats; Seminiferous Epithelium; Spermatogenesis; Testis; Urea | 2020 |
Post-stroke treatment with K-134, a phosphodiesterase 3 inhibitor, improves stroke outcomes in the stroke-prone spontaneously hypertensive rat model-A comparative evaluation of antiplatelet drugs.
Topics: Animals; Cerebral Hemorrhage; Cerebral Small Vessel Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quinolines; Rats, Inbred SHR; Risk Assessment; Stroke; Survival Rate; Treatment Outcome; Urea | 2022 |